Dr Reddys Laboratories is currently trading at Rs. 1901.00, up by 14.25 points or 0.76% from its previous closing of Rs. 1886.75 on the BSE.
The scrip opened at Rs. 1882.00 and has touched a high and low of Rs. 1910.00 and Rs. 1870.70 respectively. So far 4566 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1968.60 on 25-Jan-2013 and a 52 week low of Rs. 1528.00 on 19-Jun-2012.
Last one week high and low of the scrip stood at Rs. 1949.50 and Rs. 1875.00 respectively. The current market cap of the company is Rs. 32209.49 crore.
The promoters holding in the company stood at 25.56% while Institutions and Non-Institutions held 40.15% and 17.63% respectively.
Dr Reddy’s Laboratories has started withdrawing its muscle relaxant - tizanidine tablets, from the US market because of labeling issues. The entity has taken this decision after receiving the notification issued by United States Food and Drug Administration (FDA), and the same was intimated to the drug regulator through a letter on March 19.
The company has received the notification from FDA that, there is a possibility that the bottle labels do not contain the strength of the product as well as other printing details. Till the date 117,000 bottles are being recalled from the market by Dr Reddy’s Laboratories under a Class-III recall. The tablets are of 4 mg strength.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1938.85 |
| Dr. Reddys Labs. | 1269.80 |
| Cipla | 1441.70 |
| Zydus Lifesciences | 1159.85 |
| Lupin | 2502.90 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: